Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Benedetta Pellegrino, Andrea Herencia-Ropero, Alba Llop‐Guevara, et al.
Cancer Research (2022) Vol. 82, Iss. 8, pp. 1646-1657
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

PARP Inhibitors for Breast Cancer Treatment
Stefania Morganti, Antonio Marra, Carmine De Angelis, et al.
JAMA Oncology (2024) Vol. 10, Iss. 5, pp. 658-658
Closed Access | Times Cited: 17
Hereditary breast cancer: syndromes, tumour pathology and molecular testing
Anna Sokolova, Kate Johnstone, Amy E. McCart Reed, et al.
Histopathology (2022) Vol. 82, Iss. 1, pp. 70-82
Open Access | Times Cited: 38
RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Amanda J. Compadre, Lillian N. van Biljon, Mark C. Valentine, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 13, pp. 2466-2479
Open Access | Times Cited: 32
Mechanism of PARP inhibitor resistance and potential overcoming strategies
Xiaoyu Fu, Ping Li, Qi Zhou, et al.
Genes & Diseases (2023) Vol. 11, Iss. 1, pp. 306-320
Open Access | Times Cited: 26
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer
Giulia Martini, Valentina Belli, Stefania Napolitano, et al.
ESMO Open (2023) Vol. 8, Iss. 3, pp. 101198-101198
Open Access | Times Cited: 22
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
Andrea Herencia-Ropero, Alba Llop‐Guevara, Anna D. Staniszewska, et al.
Genome Medicine (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 11
PARPi, BRCA, and gaps: controversies and future research
Diego Dibitetto, Carmen A. Widmer, Sven Rottenberg
Trends in cancer (2024) Vol. 10, Iss. 9, pp. 857-869
Open Access | Times Cited: 10
Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial
Benedetta Pellegrino, Ettore Capoluongo, Marina Bagnoli, et al.
ESMO Open (2025) Vol. 10, Iss. 1, pp. 104091-104091
Open Access | Times Cited: 1
Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
Krista Kinneer, Philipp Wortmann, Zachary A. Cooper, et al.
Clinical Cancer Research (2022) Vol. 29, Iss. 6, pp. 1086-1101
Open Access | Times Cited: 37
Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
Antoine Simoneau, Justin L. Engel, Madhavi Bandi, et al.
Molecular Cancer Therapeutics (2022) Vol. 22, Iss. 2, pp. 215-226
Open Access | Times Cited: 33
Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes BesidesBRCA1andBRCA2as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies
Ioannis A. Voutsadakis, Athina Stravodimou
Anticancer Research (2023) Vol. 43, Iss. 3, pp. 967-981
Open Access | Times Cited: 17
Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer
Ana Veneziani, Clare L. Scott, Matthew J. Wakefield, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 16
Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
Sanna Pikkusaari, Manuela Tumiati, Anni Virtanen, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 16, pp. 3110-3123
Open Access | Times Cited: 15
A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression
Stefan J. Hutten, Roebi de Bruijn, Catrin Lutz, et al.
Cancer Cell (2023) Vol. 41, Iss. 5, pp. 986-1002.e9
Open Access | Times Cited: 15
Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma
Lara Planas‐Paz, Alicia Pliego‐Mendieta, Catherine Hagedorn, et al.
EMBO Molecular Medicine (2023) Vol. 15, Iss. 4
Open Access | Times Cited: 13
Combining Homologous Recombination-Deficient Testing and Functional RAD51 Analysis Enhances the Prediction of Poly(ADP-Ribose) Polymerase Inhibitor Sensitivity
Lea Milling Korsholm, Maj K. Kjeldsen, Lorenzo Perino, et al.
JCO Precision Oncology (2024), Iss. 8
Open Access | Times Cited: 4
Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer
Sara Torres‐Esquius, Alba Llop‐Guevara, Sara Gutiérrez‐Enríquez, et al.
JAMA Network Open (2024) Vol. 7, Iss. 4, pp. e247811-e247811
Open Access | Times Cited: 4
Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence
Sara Arce‐Gallego, Pablo Cresta Morgado, Luisa Delgado-Serrano, et al.
Cell Reports Medicine (2025), pp. 101937-101937
Open Access
Prospects and challenges of ovarian cancer organoids in chemotherapy research (Review)
Weijia Zhang, Yuqing Ding, Hui He, et al.
Oncology Letters (2025) Vol. 29, Iss. 4, pp. 1-13
Open Access
SETD1A-dependent EME1 transcription drives PARPi sensitivity in HR deficient tumour cells
Ellie Sweatman, Rachel Bayley, Richad Selemane, et al.
British Journal of Cancer (2025)
Open Access
PARP1 in Melanoma: Mechanistic Insights and Implications for Basic and Clinical Research
Andrea Marranci, Luisa Maresca, Samuele Lodovichi, et al.
Cancer Letters (2025), pp. 217599-217599
Closed Access
Predictive biomarkers for the efficacy of PARP inhibitors in ovarian cancer: an updated systematic review
Ying-Wen Wang, Isaac Allen, Gabriel Funingana, et al.
BJC Reports (2025) Vol. 3, Iss. 1
Open Access
Molecular Management of High-Grade Serous Ovarian Carcinoma
Paula Punzón-Jiménez, Víctor Lago, Santiago Domingo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 22, pp. 13777-13777
Open Access | Times Cited: 18
Personalized Systemic Therapies in Hereditary Cancer Syndromes
Luciana Mastrodomenico, Claudia Piombino, Beatrice Riccò, et al.
Genes (2023) Vol. 14, Iss. 3, pp. 684-684
Open Access | Times Cited: 10
Direct prediction of Homologous Recombination Deficiency from routine histology in ten different tumor types with attention-based Multiple Instance Learning: a development and validation study
Chiara Maria Lavinia Loeffler, Omar S.M. El Nahhas, Hannah Sophie Muti, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top